Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and ...
Christiane Eberhardt. Christiane Sigrid Eberhardt is a physician-scientist with a background in vaccine-immunology and is currently working as clinical vaccinologist at the Center ...
Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.
In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell ...
Annual Meeting, held on 7-10 December, early results from the double-blind, randomised, placebo-controlled, Phase III inMIND clinical trial were presented.
All 20 assets are trading higher. Leaders: RENDER (+13.5%) and ETC (+11.3%). Laggards: BTC (+2.4%) and ETH (+2.6%). The <a ...
Briumvi (ublituximab) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis. In England and Wales, NICE has ...
LBA-1: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase III Study (inMIND) SAN DIEGO, Dec. 10, 2024 /PRNewswire/ -- Patients with ...
Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...
These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...
Researchers sought to determine whether it would be beneficial to add inotuzumab to the CALGB 10403 pediatric regimen in the treatment of young adults with CD22-positive B-ALL.
ASH 2024 meeting. Well-tolerated treatment with no severe adverse events. Early CD8+ T cell expansion may predict positive clinical outcomes. Findings support EO2463 as a proactive treatment option ...